Sipuleucel-T

Prostate cancer is the most common cancer among men in the US, with a need for more therapies for later-stage patients. Several candidates are under investigation, including Candel Therapeutics' oncolytic virus therapy, Johnson & Johnson's Akeega (PARP inhibitor + abiraterone acetate), and Pfizer's mevrometostat (EZH2 inhibitor). These therapies aim to improve treatment options for prostate cancer patients, especially those with advanced or resistant disease.

FDA approval of lutetium-177 (177Lu) vipivotide tetraxetan (177Lu PSMA-617; Pluvicto) for metastatic castration-resistant prostate cancer (mCRPC) has led to its widespread use, with ongoing research exploring its potential in earlier disease stages. Oncologists are adapting to its regular use, focusing on patient selection via PSMA-PET scans. Early therapy with 177Lu-PSMA-617 has shown benefits in radiographical progression-free survival (rPFS) and quality of life (QOL), with ongoing trials aiming to expand its indications and improve patient outcomes.